2004 Fiscal Year Final Research Report Summary
Development of the gene therapy for the malignant brain tumor using the oncolytic herpes virus vector
| Project/Area Number |
15591535
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Single-year Grants |
|---|
| Section | 一般 |
|---|
| Research Field |
Cerebral neurosurgery
|
|---|
| Research Institution | Kumamoto University |
|---|
Principal Investigator |
NAKAMURA Hideo Kumamoto University, Medical School Dept.of Neurosurgery, Instructor, 医学部附属病院, 助手 (30359963)
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
MORIOKA Motohiro Kumamoto University, Medical School Dept.of Neurosurgery, Instructor, 医学部附属病院, 助手 (20295140)
YANO Shigetoshi Kumamoto University, Medical School Dept.of Neurosurgery, Instructor, 医学部附属病院, 助手 (60332871)
|
|---|
| Project Period (FY) |
2003 – 2004
|
| Keywords | gene therapy / Herpes virus vector / malignant brain tumor / HSV1yCD / 5-FC / 5-FU / cytosine deaminase / Oncolytic virus |
|---|
| Research Abstract |
The vector which we have developed was termed HSV1yCD and an oncolytic vector. The most unique character of this virus vector was that it can selectively infect and lyse the tumor cell but not lyse the normal cell. In other words, it can selectively destroy the tumor cells infiltrating into the normal brain. The purpose of this project was to collect the experimental data about the oncolytic virus gene therapy against the brain tumor and to utilize the data for the future clinical gene therapy. Until the year 2003 we have confirmed that HSV1yCD vector can infect the tumor cells and efficiently produce cytosine deaminase which can convert 5-FC to 5-FU. We also have confirmed that 5-FU was effective drug against glioma cells in vitro. In the year 2004 we have challenged the in vivo study using the HSV1yCD. 9L and C6 glioma cells were injected into the rat brains and subsequently the HSV1yCD was injected into the brain. Several experimentally condition has been examined and the optimal experimental methods were established. We have examined the infectious efficacy of the HSV1yCD and the oncolytic activity. Compared the contol vector, HSV1yCD could efficiently destroy the tumor cells. We also have examined the survival rate of the rats injected the tumor cells and subsequently treated with the HSV1yCD and 5-FC. We concluded the HSV1yCD may be a effective vector for the treatment of the brain tumor. Although a further investigation should be required, the HSV1yCD could be a promising tool for the future clinical tool against the brain tumor.
|
